摘要:
Provided is an HIV fusion inhibitor peptide having an amino acid sequence of any one of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO:15; and provided is a pharmaceutical composition comprising a HIV fusion inhibitor peptide and one or more of a pharmaceutically acceptable carrier and macromolecular carrier, and uses and methods of treatment provided by these compositions.
摘要翻译:本发明提供了具有SEQ ID NO:9,SEQ ID NO:10,SEQ ID NO:11,SEQ ID NO:12,SEQ ID NO:13,SEQ ID NO: 14或SEQ ID NO:15; 并且提供了包含HIV融合抑制剂肽和药学上可接受的载体和大分子载体中的一种或多种的药物组合物,以及由这些组合物提供的用途和治疗方法。
摘要:
Provided is an HIV fusion inhibitor peptide having an amino acid sequence of any one of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO:15; and provided is a pharmaceutical composition comprising a HIV fusion inhibitor peptide and one or more of a pharmaceutically acceptable carrier and macromolecular carrier, and uses and methods of treatment provided by these compositions.
摘要翻译:本发明提供了具有SEQ ID NO:9,SEQ ID NO:10,SEQ ID NO:11,SEQ ID NO:12,SEQ ID NO:13,SEQ ID NO: 14或SEQ ID NO:15; 并且提供了包含HIV融合抑制剂肽和药学上可接受的载体和大分子载体中的一种或多种的药物组合物,以及由这些组合物提供的用途和治疗方法。
摘要:
Provided is an HIV fusion inhibitor peptide having an amino acid sequence of any one of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO:15; and provided is a pharmaceutical composition comprising a HIV fusion inhibitor peptide and one or more of a pharmaceutically acceptable carrier and macromolecular carrier, and uses and methods of treatment provided by these compositions.
摘要翻译:本发明提供了具有SEQ ID NO:9,SEQ ID NO:10,SEQ ID NO:11,SEQ ID NO:12,SEQ ID NO:13,SEQ ID NO: 14或SEQ ID NO:15; 并且提供了包含HIV融合抑制剂肽和药学上可接受的载体和大分子载体中的一种或多种的药物组合物,以及由这些组合物提供的用途和治疗方法。
摘要:
Provided is an HIV fusion inhibitor peptide having an amino acid sequence of any one of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO:15; and provided is a pharmaceutical composition comprising a HIV fusion inhibitor peptide and one or more of a pharmaceutically acceptable carrier and macromolecular carrier, and uses and methods of treatment provided by these compositions.
摘要翻译:本发明提供了具有SEQ ID NO:9,SEQ ID NO:10,SEQ ID NO:11,SEQ ID NO:12,SEQ ID NO:13,SEQ ID NO: 14或SEQ ID NO:15; 并且提供了包含HIV融合抑制剂肽和药学上可接受的载体和大分子载体中的一种或多种的药物组合物,以及由这些组合物提供的用途和治疗方法。
摘要:
Synthesis of the triol of the following formula (I) from an alcohol of the formula (IV): ##STR1## via steps including protecting and then cyanating the alcohol to yield a cyanide, isomerization of the double bond, hydrolysis followed by reduction of the cyanide back to an alcohol and cis-dihydroxylation of the double bond.
摘要:
Synthesis of the triol of formula (I) or its amine-protected derivative from a cyclopentene of the formula (II) or its amine-protected derivative: ##STR1## via steps including oxidation to the aldehyde, migration of the double bond, reduction of the aldehyde moiety back to the alcohol grouping and 1,2-cis-dihydroxylation of the double bond.
摘要:
A kinetic resolution of pyridazinones of the following formula (A): ##STR1## where R.sup.1 is alkyl by enzymatic hydrolysis results in good optical purity of the phenolic product. This is significant considering the distance in the molecule (A) from the C-5 chiral center to the site of hydrolysis.
摘要:
The compound 1,8-diazabicyclo[5.4.0]undec-1(7)-enium cyanide is the reaction product of acetone cyanohydrin and 1,8-diazabicyclo [5.4.0]undec-7-ene.
摘要:
A process for removing osmium from an aqueous solution of nucleosides comprising adding hydrogen sulfide, an aromatic pi base such as pyridine, and a mineral acid. The osmium is precipitated out of solution.